The USMCA Will Keep Drug Prices Out of Reach for Patients, But Congress Can Fix It

The USMCA Creates New Barriers, Delays Patient Access to Affordable Medicines — Especially Biosimilars.

The Agreement would delay U.S. patient access to competition from low-cost, high-quality generic and biosimilar medicines, and fails to include strong incentives for their approval and uptake. 

Read Full Brief


Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.